title: Cyclosporine levels impact early rejection episodes.
authors.affiliation: Department of Surgery, University of Minnesota, Minneapolis.
authors.forename: D K
authors.initials: DK
authors.lastname: Granger
authors.forename: N B
authors.initials: NB
authors.lastname: Amin
authors.forename: A L
authors.initials: AL
authors.lastname: Sorenson
authors.forename: K J
authors.initials: KJ
authors.lastname: Gillingham
authors.forename: D M
authors.initials: DM
authors.lastname: Canafax
authors.forename: A J
authors.initials: AJ
authors.lastname: Matas
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000097:blood* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood* / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011237:Predictive Value of Tests; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone